[Thrombin-antithrombin III complexes as a measure of effective heparin treatment?].
To study the effect of heparin on thrombin formation in vivo, we measured thrombin-antithrombin III complexes (TAT) in 26 patients treated with heparin for acute coronary artery disease or deep vein thrombosis. There was a statistically significant correlation between activated partial thromboplastin time and heparin concentration, but none was found between these tests and TAT. Abnormal TAT values in 45% of the patients showed that therapeutic heparin concentration did not inhibit thrombin formation in vivo, or did so only partially.
Meyer
D
D
Gerinnungs- und Fibrinolyselaboratorium, Kantonsspital Basel.
Tsakiris
D A
DA
Marbet
G A
GA
D000990:Antithrombin III / Q000032:analysis*; D003327:Coronary Disease / Q000188:drug therapy; D006493:Heparin / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D010314:Partial Thromboplastin Time; D010447:Peptide Hydrolases / Q000032:analysis*; D013917:Thrombin / Q000096:biosynthesis; D013927:Thrombosis / Q000188:drug therapy
C046193:antithrombin III-protease complex; D000990:Antithrombin III; D006493:Heparin; D010447:Peptide Hydrolases; D013917:Thrombin
Thrombin-Antithrombin-III-Komplexe als Mass für eine wirksame Heparinbehandlung?